Uterine corpus bizarre leiomyoma

Summary

Uterine corpus bizarre leiomyoma (MONDO:0001846) is a disease. A subtype of bizarre leiomyoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine corpus bizarre leiomyoma
Mondo ID	MONDO:0001846
DOID	DOID:13958
NCIT	C40167
UMLS	C1519853
MedGen	275555
GARD	0023023
Anatomy (UBERON)	UBERON:0009853
Is cancer (heuristic)	no

Also known as: bizarre leiomyoma of body of uterus · body of uterus bizarre leiomyoma · uterine corpus bizarre leiomyoma · uterine corpus leiomyoma with bizarre nuclei · uterine corpus leiomyoma, atypical variant · uterine corpus Symplastic leiomyoma

Disease family

This is a subtype of bizarre leiomyoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm › benign smooth muscle neoplasm › leiomyoma › bizarre leiomyoma › uterine corpus bizarre leiomyoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.